{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:49:03Z","timestamp":1792518543801,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40265-025-02161-5","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:06:27Z","timestamp":1741741587000},"page":"577-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Revumenib: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"9","key":"2161_CR1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482\u201395.","journal-title":"Leukemia"},{"issue":"9","key":"2161_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11(9):162.","journal-title":"Blood Cancer J"},{"key":"2161_CR3","unstructured":"Syndax Pharmaceuticals. REVUFORJ\u00ae (revumenib) tablets, for oral use: US prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218944s000lbl.pdf. Accessed 6 Jan 2024."},{"key":"2161_CR4","unstructured":"Syndax Pharmaceuticals. Syndax announces FDA approval of Revuforj\u00ae (revumenib), the first and only menin inhibitor to treat adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A translocation [media release]. 15 Nov 2024. https:\/\/ir.syndax.com\/."},{"key":"2161_CR5","unstructured":"Syndax Pharmaceuticals. Form 10-K for the fiscal year ended December 31, 2023. https:\/\/ir.syndax.com\/annual-reports-and-proxies. Accessed 20 Jan 2025."},{"issue":"7954","key":"2161_CR6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134.","journal-title":"Nature"},{"issue":"6020","key":"2161_CR7","first-page":"1","volume":"25","author":"FRS Adriaanse","year":"2024","unstructured":"Adriaanse FRS, Schneider P, Arentsen-Peters STCJM, et al. Distinct responses to menin inhibition and synergy with DOT1L inhibition in KMT2A-rearranged acute lymphoblastic and myeloid leukemia. Int J Mol Sci. 2024;25(6020):1\u201314.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2161_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2024","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2024;43(1):75\u201384.","journal-title":"J Clin Oncol"},{"issue":"1311","key":"2161_CR9","first-page":"1","volume":"16","author":"M Fleischmann","year":"2024","unstructured":"Fleischmann M, Bechwar J, Voigtl\u00e4nder D, et al. Synergistic effects of the RARalpha agonist tamibarotene and the menin inhibitor revumenib in acute myeloid leukemia cells with KMT2A rearrangement or NPM1 Mutation. Cancers (Basel). 2024;16(1311):1\u201316.","journal-title":"Cancers (Basel)."},{"key":"2161_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00826-6","author":"W Fiskus","year":"2023","unstructured":"Fiskus W, Mill CP, Birdwell C, et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023. https:\/\/doi.org\/10.1038\/s41408-023-00826-6.","journal-title":"Blood Cancer J"},{"key":"2161_CR11","unstructured":"Zeidner JF, Lin TL, Welkie R, et al. Phase 1b study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: interim results of dose escalation from the Beat AML Consortium [abstact S134 plus presentation]. In: 29th Congress of the European Haematology Association. 2024."},{"key":"2161_CR12","unstructured":"Shukla N, Guest E, Tasian SK, et al. Safety and activity of revumenib in combination with fludarabine\/cytarabine (FLA) in patients with relapsed\/refractory acute leukemias [abstract no. P450 plus presentation]. In: 29th Congress of the European Haematology Association. 2024."},{"key":"2161_CR13","doi-asserted-by":"crossref","unstructured":"Issa GC, Cuglievan B, Daver N, et al. Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML [abstract no. 216]. In: 66th American Society of Hematology Annual Meeting. 2024.","DOI":"10.1182\/blood-2024-204375"},{"key":"2161_CR14","doi-asserted-by":"crossref","unstructured":"Loo S, Iland HJ, Tiong IS, et al. Revumenib as pre-emptive therapy for measurable residual disease in NPM1 mutated or KMT2A-rearranged acute myeloid leukemia: a domain of the multi-arm ALLG AMLM26 INTERCEPT platform trial [abstract no. 223]. In: 66th American Society of Hematology Annual Meeting. 2024.","DOI":"10.1182\/blood-2024-202895"},{"issue":"Suppl 1","key":"2161_CR15","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1182\/blood-2023-189762","volume":"142","author":"I Aldoss","year":"2023","unstructured":"Aldoss I, Issa GC, Thirman MJ, et al. Revumenib monotherapy in patients with relapsed\/refractory KMT2Ar acute leukemias: efficacy and safety results from the AUGMENT-101 phase 1\/2 study [abstract plus poster 2907]. Blood. 2023;142(Suppl 1):2907\u20139.","journal-title":"Blood"},{"issue":"Suppl 3","key":"2161_CR16","first-page":"S2","volume":"71","author":"CM Zwaan","year":"2024","unstructured":"Zwaan CM, Shukla N, Karras N, et al. Pivotal phase 2 results of AUGMENT-101 for revumenib in KMT2Ar acute leukemia: pediatric experience [abstract plus poster 2002]. Pediatr Blood Cancer. 2024;71(Suppl 3):S2\u20133.","journal-title":"Pediatr Blood Cancer"},{"key":"2161_CR17","unstructured":"Syndax Pharmaceuticals. Revumenib AUGMENT-101 pivotal data in R\/R mNPM1 AML. 2024. https:\/\/ir.syndax.com\/events\/event-details\/revumenib-augment-101-pivotal-data-rr-mnpm1-aml-call. Accessed 6 Jan 2025."},{"issue":"Suppl 1","key":"2161_CR18","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1182\/blood-2023-189036","volume":"142","author":"A Zucenka","year":"2023","unstructured":"Zucenka A, Issa GC, Arellano M, et al. Revumenib maintenance therapy following revumenib-induced remission and transplant [abstract plus poster 4950]. Blood. 2023;142(Suppl 1):4950\u20132.","journal-title":"Blood"},{"issue":"Suppl 3","key":"2161_CR19","first-page":"981","volume":"7","author":"J Rubnitz","year":"2023","unstructured":"Rubnitz J, Issa GC, Stein EM, et al. Revumenib in patients with acute leukemias: compassionate use program experience [abstract no. P561 plus poster]. HemaSphere. 2023;7(Suppl 3):981\u20132.","journal-title":"HemaSphere."},{"issue":"Suppl 3","key":"2161_CR20","doi-asserted-by":"publisher","first-page":"TPS227","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS227","volume":"42","author":"A Parikh","year":"2024","unstructured":"Parikh A, Radojcic V, Clancy M, et al. Phase 1\/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors [abstract no. TPS227]. J Clin Oncol. 2024;42(Suppl 3):TPS227.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02161-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:52:17Z","timestamp":1743288737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02161-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2161"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02161-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"12 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}